Abstract
In this issue of the Journal, a study by Heijnsdijk et al.1 shows the way to a resolution of the long-standing controversy about screening for prostate cancer. This is welcome news, since the 2009 reports of the long-awaited European and North American randomized trials of prostate-specific antigen (PSA) screening did not settle the matter.2,3 In the American trial, screening did not reduce prostate-cancer mortality, but the results were confounded by frequent PSA screening in the control group (e.g., 52% in the sixth year).3 In the European Randomized Study of Screening for Prostate Cancer, the screening of men between the . . .

This publication has 8 references indexed in Scilit: